183 related articles for article (PubMed ID: 31381810)
1. The interaction between RUNX2 and core binding factor beta as a potential therapeutic target in canine osteosarcoma.
Alegre F; Ormonde AR; Godinez DR; Illendula A; Bushweller JH; Wittenburg LA
Vet Comp Oncol; 2020 Mar; 18(1):52-63. PubMed ID: 31381810
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of copper chaperones sensitizes human and canine osteosarcoma cells to carboplatin chemotherapy.
Inkol JM; Poon AC; Mutsaers AJ
Vet Comp Oncol; 2020 Dec; 18(4):559-569. PubMed ID: 32060984
[TBL] [Abstract][Full Text] [Related]
3. Impaired cell cycle regulation of the osteoblast-related heterodimeric transcription factor Runx2-Cbfbeta in osteosarcoma cells.
San Martin IA; Varela N; Gaete M; Villegas K; Osorio M; Tapia JC; Antonelli M; Mancilla EE; Pereira BP; Nathan SS; Lian JB; Stein JL; Stein GS; van Wijnen AJ; Galindo M
J Cell Physiol; 2009 Dec; 221(3):560-71. PubMed ID: 19739101
[TBL] [Abstract][Full Text] [Related]
4. Biological activity of gemcitabine against canine osteosarcoma cell lines in vitro.
McMahon MB; Bear MD; Kulp SK; Pennell ML; London CA
Am J Vet Res; 2010 Jul; 71(7):799-808. PubMed ID: 20594083
[TBL] [Abstract][Full Text] [Related]
5. Biologic activity of the novel small molecule STAT3 inhibitor LLL12 against canine osteosarcoma cell lines.
Couto JI; Bear MD; Lin J; Pennel M; Kulp SK; Kisseberth WC; London CA
BMC Vet Res; 2012 Dec; 8():244. PubMed ID: 23244668
[TBL] [Abstract][Full Text] [Related]
6. Biological activity of dihydroartemisinin in canine osteosarcoma cell lines.
Hosoya K; Murahari S; Laio A; London CA; Couto CG; Kisseberth WC
Am J Vet Res; 2008 Apr; 69(4):519-26. PubMed ID: 18380584
[TBL] [Abstract][Full Text] [Related]
7. Pre-clinical evaluation of proteasome inhibitors for canine and human osteosarcoma.
Patatsos K; Shekhar TM; Hawkins CJ
Vet Comp Oncol; 2018 Dec; 16(4):544-553. PubMed ID: 29998615
[TBL] [Abstract][Full Text] [Related]
8. YM155 enhances the cytotoxic activity of etoposide against canine osteosarcoma cells.
Ong SM; Saeki K; Kok MK; Nakagawa T; Nishimura R
J Vet Med Sci; 2019 Aug; 81(8):1182-1190. PubMed ID: 31308291
[TBL] [Abstract][Full Text] [Related]
9. The effects of taurolidine alone and in combination with doxorubicin or carboplatin in canine osteosarcoma in vitro.
Marley K; Helfand SC; Edris WA; Mata JE; Gitelman AI; Medlock J; Séguin B
BMC Vet Res; 2013 Jan; 9():15. PubMed ID: 23331343
[TBL] [Abstract][Full Text] [Related]
10. The effects of sulforaphane on canine osteosarcoma proliferation and invasion.
Rizzo VL; Levine CB; Wakshlag JJ
Vet Comp Oncol; 2017 Sep; 15(3):718-730. PubMed ID: 27045198
[TBL] [Abstract][Full Text] [Related]
11. Effects of lycopene on proliferation and death of canine osteosarcoma cells.
Wakshlag JJ; Balkman CE
Am J Vet Res; 2010 Nov; 71(11):1362-70. PubMed ID: 21034328
[TBL] [Abstract][Full Text] [Related]
12. Identification of anti-proliferative kinase inhibitors as potential therapeutic agents to treat canine osteosarcoma.
Mauchle U; Selvarajah GT; Mol JA; Kirpensteijn J; Verheije MH
Vet J; 2015 Aug; 205(2):281-7. PubMed ID: 25190293
[TBL] [Abstract][Full Text] [Related]
13. Effects of the potassium-sparing diuretic amiloride on chemotherapy response in canine osteosarcoma cells.
Poon AC; Inkol JM; Luu AK; Mutsaers AJ
J Vet Intern Med; 2019 Mar; 33(2):800-811. PubMed ID: 30556178
[TBL] [Abstract][Full Text] [Related]
14. Investigation of the effects of deracoxib and piroxicam on the in vitro viability of osteosarcoma cells from dogs.
Royals SR; Farese JP; Milner RJ; Lee-Ambrose L; van Gilder J
Am J Vet Res; 2005 Nov; 66(11):1961-7. PubMed ID: 16334957
[TBL] [Abstract][Full Text] [Related]
15. Melarsomine suppresses canine osteosarcoma cell survival via inhibition of Hedgehog-GLI signaling.
Nam A; Kim T; Li Q; Rebhun RB; Youn HY; Seo KW
J Vet Med Sci; 2019 Dec; 81(12):1722-1729. PubMed ID: 31645504
[TBL] [Abstract][Full Text] [Related]
16. Enrofloxacin enhances the effects of chemotherapy in canine osteosarcoma cells with mutant and wild-type p53.
York D; Withers SS; Watson KD; Seo KW; Rebhun RB
Vet Comp Oncol; 2017 Sep; 15(3):1087-1100. PubMed ID: 27333821
[TBL] [Abstract][Full Text] [Related]
17. 17-AAG and Apoptosis, Autophagy, and Mitophagy in Canine Osteosarcoma Cell Lines.
Massimini M; Palmieri C; De Maria R; Romanucci M; Malatesta D; De Martinis M; Maniscalco L; Ciccarelli A; Ginaldi L; Buracco P; Bongiovanni L; Della Salda L
Vet Pathol; 2017 May; 54(3):405-412. PubMed ID: 28438108
[TBL] [Abstract][Full Text] [Related]
18. Effects of etoposide alone and in combination with piroxicam on canine osteosarcoma cell lines.
Ong SM; Saeki K; Tanaka Y; Nishimura R; Nakagawa T
Vet J; 2016 Dec; 218():51-59. PubMed ID: 27938709
[TBL] [Abstract][Full Text] [Related]
19. Induction of VEGF by tepoxalin does not lead to increased tumour growth in a canine osteosarcoma xenograft.
Sottnik JL; Hansen RJ; Gustafson DL; Dow SW; Thamm DH
Vet Comp Oncol; 2011 Jun; 9(2):118-30. PubMed ID: 21569197
[TBL] [Abstract][Full Text] [Related]
20. Carboplatin versus alternating carboplatin and doxorubicin for the adjuvant treatment of canine appendicular osteosarcoma: a randomized, phase III trial.
Skorupski KA; Uhl JM; Szivek A; Allstadt Frazier SD; Rebhun RB; Rodriguez CO
Vet Comp Oncol; 2016 Mar; 14(1):81-7. PubMed ID: 24118677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
